Chronic Obstructive Pulmonary Disease or COPD refers to a group of lung diseases that block airflow and make breathing difficult. It includes emphysema and chronic bronchitis. The main symptoms include breathing difficulty, chronic cough, mucus (sputum) production, and wheezing. The primary cause of COPD is long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. Other causes may include air pollution, chemical fumes, or genetic factors. COPD treatment aims to manage symptoms and prevent future complications. It includes the use of bronchodilators, corticosteroids, vaccines, and oxygen therapy.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 18.1 Bn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Growing adoption of novel combination therapies for COPD treatment is expected to drive the market growth over the forecast period. Combination therapies use two or more drugs that work in different ways to control COPD symptoms. For example, combining a long-acting bronchodilator with an inhaled corticosteroid provides better symptom relief and reduces exacerbations compared to either medication alone. Furthermore, approval and commercialization of new drug formulations for COPD is also fueling the market. For instance, in June 2022, the FDA approved an upgraded dry powder inhaler called Trelegy Ellipta for COPD maintenance treatment. Trelegy contains a fixed-dose combination of fluticasone furoate, umeclidinium, and vilanterol in a single inhalation device. Such novel drug delivery systems eliminate coordination challenges associated with multiple inhalers.
The global chronic obstructive pulmonary disease (COPD) treatment market is dominated by the maintenance/relievers sub-segment. This sub-segment accounts for over 40% of the market share owing to the easy availability of reliever medications for immediate relief from COPD symptoms such as breathlessness. The preventers sub-segment holds the second largest share as it helps prevent symptoms from recurring and exacerbating.
Political: Governments across major countries are focusing on increasing awareness about COPD through various campaigns and initiatives. They are also supporting the development of advanced treatment options through favorable regulations.
Economic: Rising healthcare spending along with growing disposable incomes has been fueling the demand for superior COPD medications. However, high treatment costs remain a challenge, especially in developing regions.
Social: Growing pollution levels, rising prevalence of smoking and aging population have significantly increased the risk of COPD globally. Various social stigma also restrict patients from timely diagnosis and management of the condition.
Technological: Bioelectronic medicines, smart inhalers, and sensor-based monitoring devices are some emerging technological advances helping improve the management of COPD. However, overall innovation in this field remains moderate.
The Global COPD Treatment Market Share is expected to witness high growth over the forecast period of 2023 to 2030. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 18.1 Bn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030.
The Asia Pacific region holds around 30% share of the global COPD treatment market and is anticipated to continue dominating in the coming years. China, India, and other Southeast Asian countries contribute majorly to the regional market growth due to their large population sizes afflicted by COPD. Increasing medical accessibility in rural regions along with various collaborations between local and international pharmaceutical players are expanding the regional market reach.
Key players operating in the chronic obstructive pulmonary disease (COPD) treatment market are GlaxoSmithKline, Novartis AG, Merck & Co, AstraZeneca, and Boehringer Ingelheim. GSK is a top player due to their extensive portfolio of maintenance and rescue medication brands like Breo Ellipta, Incruse Ellipta, and others. Novartis leads with its Spiriva brand while Merck’s Dulera is a blockbuster preventer medication in this market.